Proactive Investors - Run By Investors For Investors

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene unit in collaboration deal with Oregon State University

FuturaGene PLC (AIM: FGN)  said its unit CBD Technologies Ltd has entered into a collaborative agreement with Oregon State University under which it will provide professor Steven Strauss’ research group at the Forest Biotechnology department with a proprietary eucalyptus clone and a highly efficient eucalyptus transformation protocol.

The collaboration will facilitate rapid and efficient evaluation of genes for flowering control and other biosafety aspects of tree modification.

In addition CBD Tech plans to join the Tree Biosafety and Genomics Research Cooperative (TBGRC), an internationally recognised tree research consortium that has been working with forest industries on tree biotechnology for 15 years and which is directed by Professor Strauss.

Although eucalyptus is the most widely planted commercial plantation tree species for pulp and paper production in the world, this species is notoriously difficult to transform, FurturaGene said in a statement.

Thus, the supply of a proprietary clone and transformation method from the company to a public research institute, under appropriate material usage and confidentiality provisions, represents a significant contribution to accelerating public research and development in this species, it added.

Register here to be notified of future FGN Company articles


Related Articles

January 22

Shares in ImmuPharma rose 20% after the AIM listed drug developer revealed it is ready to take its lead treatment into the final stage of clinical trials.

February 19

Ergomed has agreed to co-develop a drug in a deal that will see it receive a stake in its partner, Sweden’s Dilaforette.

February 02

'Buy and build' drugs group is paying £5.5mln for MacuVision, which makes a supplement for sufferers of dry macular degeneration.

© Proactive Investors 2015